Coldstream Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Coldstream Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$644K	Sell	3,404 -682	-17%	-$119K	0.01%	620
2025 Q4	$695K	Sell	4,086 -386	-9%	-$59.2K	0.01%	570
2025 Q3	$589K	Buy	4,472 +1,195	+36%	+$143K	0.01%	666
2025 Q2	$348K	Sell	3,277 -399	-11%	-$43.3K	0.01%	809
2025 Q1	$456K	Buy	3,676 +299	+9%	+$39K	0.01%	651
2024 Q4	$416K	Buy	3,377 +1,077	+47%	+$127K	0.01%	681
2024 Q3	$259K	Buy	2,300 +165	+8%	+$18.1K	0.01%	910
2024 Q2	$228K	Buy	2,135 +299	+16%	+$32.9K	0.01%	885
2024 Q1	$221K	Sell	1,836 -8	-0.4%	-$980	0.01%	908
2023 Q4	$227K	Buy	+1,844	New	+$230K	0.01%	836
2023 Q2	–	Sell	-1,758	Closed	-$257K	–	848
2023 Q1	$257K	Sell	1,758 -58	-3%	-$8.58K	0.01%	676
2022 Q4	$289K	Buy	+1,816	New	+$266K	0.01%	612
2022 Q2	$340K	Buy	2,174 +826	+61%	+$127K	0.01%	514
2022 Q1	$210K	Buy	+1,348	New	+$196K	0.01%	732

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Coldstream Capital Management's JAZZ Position: Q1 2026 in Review

Coldstream Capital Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 17% in Q1 2026, selling an estimated $119K and leaving 3,404 shares worth $644K. The position accounts for 0.01% of the portfolio, ranked #620.

Coldstream Capital Management first reported a position in JAZZ in Q1 2022 and has held it in 14 quarters since. The position peaked at $695K in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Coldstream Capital Management held 3,404 shares of Jazz Pharmaceuticals worth $644K as of Q1 2026.
Coldstream Capital Management sold 682 Jazz Pharmaceuticals shares in Q1 2026, an estimated $119K.
Jazz Pharmaceuticals made up 0.01% of Coldstream Capital Management's portfolio in Q1 2026, its #620 holding.
Coldstream Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
Coldstream Capital Management's Jazz Pharmaceuticals position peaked at $695K in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.